James Robinson
Chief Executive Officer, A2 Biotherapeutics
James Robinson is Chief Executive Officer and member of the board of directors of A2 Biotherapeutics, a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to address the high unmet needs in cancer. Robinson joined A2 Bio in April 2024 to accelerate the company’s progress in driving its innovative platform to advance promising therapies to patients.
With over 30 years of experience in the biopharmaceutical industry, Robinson has excelled in building and leading organizations from inception to commercial success, while also demonstrating an enduring commitment to making a meaningful impact on the lives of patients and their families suffering from some of the most devastating medical conditions.
Robinson previously served as President and Chief Executive Officer of the former Urovant Sciences (now Sumitomo Pharma America, Inc.) from March 2020 to July 2023, guiding the company through its first product launch and subsequent acquisition by Sumitovant Biopharma in March 2021. He served as a member of the Urovant board of directors before his appointment as President and CEO in March 2020. Previously, Robinson served as President and COO of Paragon Biosciences. Prior to Paragon, Robinson was the President and COO of Alkermes plc. He spent over 12 years at Astellas Pharma, one of the leaders in the fields of urology, oncology and solid organ transplant, where he served as President of the Americas, and was responsible for approximately $4 billion in revenue generation. He started his career at Schering-Plough Pharmaceuticals.
Robinson serves as a member of the Board of Directors of Petauri Health, Eledon Pharmaceuticals, Inc., and UroGen Pharma Ltd. He is a 2023 recipient of PM360’s Trailblazer Award for CEO of the Year (in the Life Sciences Manufacturer category).
Robinson earned a Bachelor of Science degree in marketing from DePaul University.